|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rich JN: Cancer stem cells: Understanding
tumor hierarchy and heterogeneity. Medicine (Baltimore). 95 (1
Suppl 1):S2–S7. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leeman KT, Fillmore CM and Kim CF: Lung
stem and progenitor cells in tissue homeostasis and disease. Curr
Top Dev Biol. 107:207–233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salama R, Tang J, Gadgeel SM, Ahmad A and
Sarkar FH: Lung cancer stem cells: Current progress and future
perspectives. J Stem Cell Res Ther S7. 0072012.
|
|
6
|
Luo J, Zhou X and Yakisich JS: Stemness
and plasticity of lung cancer cells: Paving the road for better
therapy. Onco Targets Ther. 7:1129–1134. 2014.PubMed/NCBI
|
|
7
|
Wang Y, Jiang M, Du C, Yu Y, Liu Y, Li M
and Luo F: Utilization of lung cancer cell lines for the study of
lung cancer stem cells. Oncol Lett. 15:6791–6798. 2018.PubMed/NCBI
|
|
8
|
Halim NHA, Zakaria N, Satar NA and Yahaya
BH: Isolation and characterization of cancer stem cells of the
non-small-cell lung cancer (A549) cell line. Methods Mol Biol.
1516:371–388. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haigis MC and Sinclair DA: Mammalian
sirtuins: Biological insights and disease relevance. Annu Rev
Pathol. 5:253–295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mei Z, Zhang X, Yi J, Huang J, He J and
Tao Y: Sirtuins in metabolism, DNA repair and cancer. J Exp Clin
Cancer Res. 35:1822016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang HZ, Lin XG, Hua P, Wang M, Ao X,
Xiong LH, Wu C and Guo JJ: The study of the tumor stem cell
properties of CD133+CD44+ cells in the human lung adenocarcinoma
cell line A549. Cell Mol Biol (Noisy-le-grand). 56
(Suppl):OL1350–OL1358. 2010.PubMed/NCBI
|
|
13
|
Leung EL, Fiscus RR, Tung JW, Tin VP,
Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP: Non-small cell lung
cancer cells expressing CD44 are enriched for stem cell-like
properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tirino V, Camerlingo R, Franco R, Malanga
D, La Rocca A, Viglietto G, Rocco G and Pirozzi G: The role of
CD133 in the identification and characterisation of
tumour-initiating cells in non-small-cell lung cancer. Eur J
Cardiothorac Surg. 36:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chao SC, Chen YJ, Huang KH, Kuo KL, Yang
TH, Huang KY, Wang CC, Tang CH, Yang RS and Liu SH: Induction of
sirtuin-1 signaling by resveratrol induces human chondrosarcoma
cell apoptosis and exhibits antitumor activity. Sci Rep.
7:31802017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Li J, Cao N, Li Z, Han J and Li L:
Resveratrol, an activator of SIRT1, induces protective autophagy in
non-small-cell lung cancer via inhibiting Akt/mTOR and activating
p38-MAPK. Onco Targets Ther. 11:7777–7786. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Wan F, You W, Tan X, Liu G, Jin
Q, Wei C, Liu X, Zhao H, Liu Y and Zhang C: Comparison of apoptosis
between bovine subcutaneous and intramuscular adipocytes by
resveratrol via SIRT1. Anim Biotechnol. 1–9. 2019. View Article : Google Scholar
|
|
18
|
Yun JM, Chien A, Jialal I and Devaraj S:
Resveratrol up-regulates SIRT1 and inhibits cellular oxidative
stress in the diabetic milieu: Mechanistic insights. J Nutr
Biochem. 23:699–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chai R, Fu H, Zheng Z, Liu T, Ji S and Li
G: Resveratrol inhibits proliferation and migration through SIRT1
mediated post-translational modification of PI3K/AKT signaling in
hepatocellular carcinoma cells. Mol Med Rep. 16:8037–8044. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frazzi R, Valli R, Tamagnini I, Casali B,
Latruffe N and Merli F: Resveratrol-mediated apoptosis of hodgkin
lymphoma cells involves SIRT1 inhibition and FOXO3a
hyperacetylation. Int J Cancer. 132:1013–1021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pacholec M, Bleasdale JE, Chrunyk B,
Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis
P, Pabst B, et al: SRT1720, SRT2183, SRT1460, and resveratrol are
not direct activators of SIRT1. J Biol Chem. 285:8340–8351. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bi X, Ye Q, Li D, Peng Q, Wang Z, Wu X,
Zhang Y, Zhang Q and Jiang F: Inhibition of nucleolar stress
response by Sirt1: A potential mechanism of acetylation-independent
regulation of p53 accumulation. Aging Cell. 18:e129002019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Wang D and Zhao Y: Effect and
mechanism of resveratrol on the apoptosis of lung adenocarcinoma
cell line A549. Cell Biochem Biophys. 73:527–531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan L, Zhang Y, Xia J, Liu B, Zhang Q,
Liu J, Luo L, Peng Z, Song Z and Zhu R: Resveratrol induces cell
cycle arrest via a p53-independent pathway in A549 cells. Mol Med
Rep. 11:2459–2464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lahusen TJ and Deng CX: SRT1720 induces
lysosomal-dependent cell death of breast cancer cells. Mol Cancer
Ther. 14:183–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirai S, Endo S, Saito R, Hirose M, Ueno
T, Suzuki H, Yamato K, Abei M and Hyodo I: Antitumor effects of a
sirtuin inhibitor, tenovin-6, against gastric cancer cells via
death receptor 5 up-regulation. PLoS One. 9:e1028312014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ueno T, Endo S, Saito R, Hirose M, Hirai
S, Suzuki H, Yamato K and Hyodo I: The sirtuin inhibitor tenovin-6
upregulates death receptor 5 and enhances cytotoxic effects of
5-fluorouracil and oxaliplatin in colon cancer cells. Oncol Res.
21:155–164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Kim TH, Ahn MY, Lee J, Jung JH,
Choi WS, Lee BM, Yoon KS, Yoon S and Kim HS: Sirtinol, a class III
HDAC inhibitor, induces apoptotic and autophagic cell death in
MCF-7 human breast cancer cells. Int J Oncol. 41:1101–1109. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
MacCallum SF, Groves MJ, James J, Murray
K, Appleyard V, Prescott AR, Drbal AA, Nicolaou A, Cunningham J,
Haydock S, et al: Dysregulation of autophagy in chronic lymphocytic
leukemia with the small-molecule sirtuin inhibitor tenovin-6. Sci
Rep. 3:12752013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Solomon JM, Pasupuleti R, Xu L, McDonagh
T, Curtis R, DiStefano PS and Huber LJ: Inhibition of SIRT1
catalytic activity increases p53 acetylation but does not alter
cell survival following DNA damage. Mol Cell Biol. 26:28–38. 2006.
View Article : Google Scholar : PubMed/NCBI
|
